Ryvu Therapeutics (WAR:RVU) ROE % Adjusted to Book Value : -14.08% (As of Dec. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Ryvu Therapeutics ROE % Adjusted to Book Value?

Ryvu Therapeutics's ROE % for the quarter that ended in Dec. 2024 was -87.18%. Ryvu Therapeutics's PB Ratio for the quarter that ended in Dec. 2024 was 6.19. Ryvu Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -14.08%.

Ryvu Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Ryvu Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ryvu Therapeutics ROE % Adjusted to Book Value Chart

Ryvu Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-4.51

-6.02

-12.62

-5.97

-8.92

Ryvu Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-7.94	-5.23	-10.75	-8.21	-14.08

Competitive Comparison of Ryvu Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Ryvu Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ryvu Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Ryvu Therapeutics's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Ryvu Therapeutics ROE % Adjusted to Book Value Calculation

Ryvu Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-55.24%	/	6.19
	=	-8.92%

Ryvu Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-87.18%	/	6.19
	=	-14.08%

Ryvu Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Ryvu Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Ryvu Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (WAR:RVU) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

9Y4:Germany

Address

Leona Henryka Sternbacha 2, Krakow, POL, 30-394

Website

https://www.ryvu.com

Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.

Ryvu Therapeutics Headlines

No Headlines